Cargando…

Approved and Emerging Disease Modifying Therapies on Neurodegeneration in Multiple Sclerosis

Multiple sclerosis (MS) is an autoimmune, chronic, progressive disease leading to a combination of inflammation, demyelination, and neurodegeneration throughout the central nervous system (CNS). The outcome of these processes can be visualized in magnetic resonance imaging (MRI) scans as brain atrop...

Descripción completa

Detalles Bibliográficos
Autores principales: Bross, Madeline, Hackett, Melody, Bernitsas, Evanthia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7348940/
https://www.ncbi.nlm.nih.gov/pubmed/32560364
http://dx.doi.org/10.3390/ijms21124312
_version_ 1783556948166180864
author Bross, Madeline
Hackett, Melody
Bernitsas, Evanthia
author_facet Bross, Madeline
Hackett, Melody
Bernitsas, Evanthia
author_sort Bross, Madeline
collection PubMed
description Multiple sclerosis (MS) is an autoimmune, chronic, progressive disease leading to a combination of inflammation, demyelination, and neurodegeneration throughout the central nervous system (CNS). The outcome of these processes can be visualized in magnetic resonance imaging (MRI) scans as brain atrophy, or brain volume loss (BVL), as well as lesions, “black holes” and spinal cord atrophy. MRI outcomes such as BVL have been used as biomarkers of neurodegeneration and other measures of MS disease progression in clinical research settings. Several FDA-approved medications seek to alleviate disease progression by reducing the impact of such factors as demyelination and neurodegeneration, but there are still many shortcomings that current clinical research aims to mitigate. This review attempts to provide an overview of the FDA-approved medications available for treating multiple sclerosis and their effect on neurodegeneration, measured by BVL.
format Online
Article
Text
id pubmed-7348940
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-73489402020-07-15 Approved and Emerging Disease Modifying Therapies on Neurodegeneration in Multiple Sclerosis Bross, Madeline Hackett, Melody Bernitsas, Evanthia Int J Mol Sci Review Multiple sclerosis (MS) is an autoimmune, chronic, progressive disease leading to a combination of inflammation, demyelination, and neurodegeneration throughout the central nervous system (CNS). The outcome of these processes can be visualized in magnetic resonance imaging (MRI) scans as brain atrophy, or brain volume loss (BVL), as well as lesions, “black holes” and spinal cord atrophy. MRI outcomes such as BVL have been used as biomarkers of neurodegeneration and other measures of MS disease progression in clinical research settings. Several FDA-approved medications seek to alleviate disease progression by reducing the impact of such factors as demyelination and neurodegeneration, but there are still many shortcomings that current clinical research aims to mitigate. This review attempts to provide an overview of the FDA-approved medications available for treating multiple sclerosis and their effect on neurodegeneration, measured by BVL. MDPI 2020-06-17 /pmc/articles/PMC7348940/ /pubmed/32560364 http://dx.doi.org/10.3390/ijms21124312 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Bross, Madeline
Hackett, Melody
Bernitsas, Evanthia
Approved and Emerging Disease Modifying Therapies on Neurodegeneration in Multiple Sclerosis
title Approved and Emerging Disease Modifying Therapies on Neurodegeneration in Multiple Sclerosis
title_full Approved and Emerging Disease Modifying Therapies on Neurodegeneration in Multiple Sclerosis
title_fullStr Approved and Emerging Disease Modifying Therapies on Neurodegeneration in Multiple Sclerosis
title_full_unstemmed Approved and Emerging Disease Modifying Therapies on Neurodegeneration in Multiple Sclerosis
title_short Approved and Emerging Disease Modifying Therapies on Neurodegeneration in Multiple Sclerosis
title_sort approved and emerging disease modifying therapies on neurodegeneration in multiple sclerosis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7348940/
https://www.ncbi.nlm.nih.gov/pubmed/32560364
http://dx.doi.org/10.3390/ijms21124312
work_keys_str_mv AT brossmadeline approvedandemergingdiseasemodifyingtherapiesonneurodegenerationinmultiplesclerosis
AT hackettmelody approvedandemergingdiseasemodifyingtherapiesonneurodegenerationinmultiplesclerosis
AT bernitsasevanthia approvedandemergingdiseasemodifyingtherapiesonneurodegenerationinmultiplesclerosis